Orionis Biosciences Secures $55 Million Financing to Support Advancement into Clinic

Funding will progress Orionis' tunable precision medicines pipeline, with anticipated IND submission and start of conditionally active cytokine Phase 1 trial in 2023 Robert Petit joins as Head of

Related Keywords

New York ,United States ,Boston ,Massachusetts ,Nikolai Kley ,Bihua Chen ,Bristol Meyers Squibb ,Orionis Bio ,Robert Petit ,Kostenloser Wertpapierhandel ,Riccardo Sabatini ,Orionis Biosciences ,Indiana State University ,Head Of Early Clinical Development ,Fudan University ,Early Clinical Development ,Wharton School Of The University Pennsylvania ,Ohio State University College Of Medicine ,Novartis ,Senior Vice President ,Orionis Board ,Cormorant Asset Management ,Chief Executive Officer ,Early Clinical ,Ohio State University College ,Indiana State ,Wharton School ,Graduate School ,Medical Sciences ,Cornell Medical College ,Annual Targeted Protein Degradation ,Monovalent Molecular Glues ,Chief Data Scientist ,Bridge Communications ,Orionis ,Iosciences ,Ecures ,Billion ,Financing ,Support ,Advancement ,Clinic ,